Cartesian Therapeutics (RNAC) Operating Expenses: 2015-2025
Historic Operating Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $21.5 million.
- Cartesian Therapeutics' Operating Expenses rose 19.80% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.6 million, marking a year-over-year decrease of 8.72%. This contributed to the annual value of $82.8 million for FY2024, which is 26.34% down from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Operating Expenses is $21.5 million, which was down 2.67% from $22.1 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Operating Expenses registered a high of $44.6 million during Q4 2023, and its lowest value of $18.0 million during Q3 2024.
- Over the past 3 years, Cartesian Therapeutics' median Operating Expenses value was $22.1 million (recorded in 2025), while the average stood at $23.8 million.
- As far as peak fluctuations go, Cartesian Therapeutics' Operating Expenses spiked by 76.34% in 2023, and later tumbled by 41.76% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Operating Expenses (Quarterly) stood at $25.9 million in 2021, then decreased by 2.20% to $25.3 million in 2022, then skyrocketed by 76.34% to $44.6 million in 2023, then tumbled by 41.76% to $26.0 million in 2024, then grew by 19.80% to $21.5 million in 2025.
- Its last three reported values are $21.5 million in Q3 2025, $22.1 million for Q2 2025, and $23.0 million during Q1 2025.